1. Introduction {#sec1-marinedrugs-16-00210}
===============

Soft corals including those of the genus *Sarcophyton* have been well recognized to be a rich source of structurally unique and bioactive diterpenes, in particular cembranoids \[[@B1-marinedrugs-16-00210]\]. Since the first report of sarcophine, a cembrane with a α,β-unsaturated γ-lactone ring \[[@B2-marinedrugs-16-00210]\], series of cembrane-derived terpenoids, such as cembranes with *trans-* \[[@B3-marinedrugs-16-00210],[@B4-marinedrugs-16-00210]\] or *cis-* \[[@B4-marinedrugs-16-00210],[@B5-marinedrugs-16-00210]\] fused α-methylene-γ-lactone rings or with the same γ-lactone ring as in sarcophine \[[@B6-marinedrugs-16-00210],[@B7-marinedrugs-16-00210],[@B8-marinedrugs-16-00210]\] have been discovered from the worldwide investigation of *Sarcophyton* species. Furthermore, some structurally complex biscembranes derived from Diels--Alder reaction also have been unveiled \[[@B9-marinedrugs-16-00210],[@B10-marinedrugs-16-00210],[@B11-marinedrugs-16-00210]\]. Recently, many cembranoids possessing new structures have been isolated from soft corals \[[@B12-marinedrugs-16-00210],[@B13-marinedrugs-16-00210],[@B14-marinedrugs-16-00210],[@B15-marinedrugs-16-00210],[@B16-marinedrugs-16-00210],[@B17-marinedrugs-16-00210],[@B18-marinedrugs-16-00210],[@B19-marinedrugs-16-00210],[@B20-marinedrugs-16-00210]\]. Accordingly, more cembranoids with promising bioactivities have been reported \[[@B21-marinedrugs-16-00210],[@B22-marinedrugs-16-00210],[@B23-marinedrugs-16-00210],[@B24-marinedrugs-16-00210],[@B25-marinedrugs-16-00210],[@B26-marinedrugs-16-00210]\]. Thus, further investigation on new cembranoids and bioactivities might warrant further biomedical research. As a recent publication reported the isolation of four cembranes possessing only simple functional groups from *Sarcophyton stellatum* \[[@B27-marinedrugs-16-00210]\], we further investigated the secondary metabolites of the same coral collected from Dongsha Atoll in order to search for bioactive and new metabolites for further medicinal study. This investigation led to the discovery of six new cembranoid diterpenes: stellatumolides A--C (**1**--**3**), stellatumonins A and B (**4** and **5**), and stellatumonone (**6**), along with ten known related compounds (**7**--**16**). The assay for in vitro anti-inflammatory activity of the isolated compounds showed that (+)-sarcophine (**9**) could reduce the accumulation of the proinflammatory cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) proteins.

2. Results and Discussion {#sec2-marinedrugs-16-00210}
=========================

The ethyl acetate (EtOAc) extract of *S. stellatum* was initially fractionated over a silica gel column, and the obtained fractions were then separated and purified by repeated column chromatography to yield new cembranoids **1**--**6** ([Figure 1](#marinedrugs-16-00210-f001){ref-type="fig"}), and structures were elucidated on the basis of spectroscopic analyses ([Supplementary Materials, Figures S1--S47](#app1-marinedrugs-16-00210){ref-type="app"}).

Stellatumolide A (**1**), \[α\]${}_{D}^{25}$ + 57.2, (*c* 0.1, CHCl~3~), was isolated as a colorless oil and exhibited a sodium adduct ion peak at *m/z* 371.1832 \[M + Na\]^+^ from high-resolution electrospray ionization mass spectrometry (HRESIMS). Thus, the molecular formula C~20~H~28~O~5~ was established. The infrared (IR) absorption band at ν~max~ 3445 cm^−1^ and the ion peak appearing in the ESIMS at *m/z* 353 \[M − H~2~O + Na\]^+^ indicated the presence of one hydroxy group in the molecule. The 20 carbon signals in the ^13^C nuclear magnetic resonance (NMR) spectrum ([Table 1](#marinedrugs-16-00210-t001){ref-type="table"}) were attributable to four methyls, six methylenes, three methines (including two oxy- and one olefinic CH), and seven nonprotonated carbons (including three olefinic, three *sp^3^* oxygenated carbons, and one carbonyl carbon). The α,β-unsaturated γ-lactone moiety was deduced from NMR signals at *δ*~C~ 171.1, 157.9, and 128.8 (each C), and IR absorption at ν~max~ 1760 and 1680 cm^−1^. Moreover, one trisubstituted double bond was found by NMR signals at *δ*~C~ 130.6 (C), 129.2 (CH), and *δ*~H~ 5.26 (1H, d, *J* = 11.0 Hz) ([Table 2](#marinedrugs-16-00210-t002){ref-type="table"}). The correlation spectroscopy (COSY) spectrum of **1** revealed the presence of three consecutive spin systems ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}). The heteronuclear multiple bond correlations (HMBC) from H~3~-17 to the carbonyl carbon (*δ*~C~ 171.1, C), C-1 (*δ*~C~ 157.9, C), and C-15 (*δ*~C~ 128.8, C); H~3~-18 to C-3, C-4, and C-5; H~3~-19 to C-7, C-8, and C-9; and H~3~-20 to C-11, C-12, and C-13 established the carbon skeleton of **1**. The unresolved 2H signal (*δ*~H~ 4.27) present in the ^1^H NMR spectrum, measured in CDCl~3~, could be well resolved by measuring **1** in C~6~D~6~ (Experimental Section), resulting in two signals at *δ*~H~ 4.19 (1H, s) and 3.93 (1H, d, *J* = 10.0 Hz), which were further assigned to oxymethines H-3 and H-7, respectively. Therefore, the HMBC correlation from H-3 to C-8 clearly indicated an ether linkage between C-3 and C-8 ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}). In consideration of the seven degrees of unsaturation and the molecular formula of **1**, an additional ether linkage was placed between the ketal carbon C-2 and C-4. By further comparison of the ^13^C NMR spectroscopic data of **1** with those of a spiro oxetanebutenolide derivative ramariolide B \[[@B28-marinedrugs-16-00210]\], two signals of nonprotonated *sp^3^* oxycarbons resonating at *δ*~C~ 113.4 and 92.2 for C-2 and C-4 of **1**, relative to those at *δ*~C~ 112.7 and 90.7 for corresponding carbons, established an unusual spiroketal unit between the oxetane (C-2/C-4) and the γ-lactone ring (C-2/C-16) of **1**. From the above findings, detailed HMBC spectrum ([Figure 3](#marinedrugs-16-00210-f003){ref-type="fig"}), and 2D NMR correlation analysis ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}), the planar structure of **1** was established.

The relative configurations at C-2, C-3, C-4, C-7, and C-8 of **1** were proposed from analysis of nuclear Overhauser effect spectroscopy (NOESY) ([Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}, molecular structures are energy-minimized using MM2 force field method). A strong NOE interaction of H-3 (*δ*~H~ 4.19, s) with H-7 (*δ*~H~ 3.93, br d, *J* = 10.0 Hz), measured in C~6~D~6~ ([Figure 3](#marinedrugs-16-00210-f003){ref-type="fig"} and [Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}), indicated that both protons should be positioned on the same face and were arbitrarily assigned as β-oriented. Thus, the significant NOE correlation of H-3 with one of the H~2~-14 (*δ*~H~ 2.12, dd, *J =* 13.0, 13.0 Hz) established the β-orientation of the C-1 residue in the oxetane, and hence the *R\** configuration of C-2. Furthermore, one of the methylene protons at C-6 (*δ*~H~ 1.22, m) exhibited a NOESY correlation with H-7, and was therefore characterized as H-6β, while the other (*δ*~H~ 1.50, m) was assigned as H-6α. H-6α showed NOE interactions with both H~3~-18 and H~3~-19; therefore, H~3~-18 and H~3~-19 were also positioned on the α-face. Due to the high flexibility of the macrocycle ring structure of **1**, a conformational search at the molecular mechanics level was carried out using CONFLEX^®^ \[[@B29-marinedrugs-16-00210],[@B30-marinedrugs-16-00210]\] software (CONFLEX 7.0, Conflex Corp., Tokyo, Japan) with the MMFF94s force field. As a result, a total of 18 conformers were determined. Three of these conformers were found to be the most populated ([Figure 5](#marinedrugs-16-00210-f005){ref-type="fig"}) and fulfilled the observed NOESY correlations ([Figure 3](#marinedrugs-16-00210-f003){ref-type="fig"} and [Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}). In these conformers, the splitting pattern (br d) and the coupling constant (*J* value = 10.0 Hz) displayed by H-7 in **1** could be thus explained as a function of the dihedral angles 179.7° and 66.2° formed with the adjacent 6-CH~2~ protons (H*~trans~* and H*~cis~*; *J* = 10--15 and 0--2 Hz, respectively). Finally, the *Z* and *E* geometries of the C-1/C-15 and C-11/C-12 double bonds in **1**, respectively, were established by the NOE interaction of H~3~-17 (*δ*~H~ 1.49, s) with H-14 (*δ*~H~ 2.01, ddd, *J* = 13.0, 8.0, 8.0 Hz) and the upfield shift of C-20 (*δ*~C~ 16.5 in CDCl~3~), respectively. The above results revealed that **1** possesses a structure in good agreement with that shown in formula **1** ([Figure 1](#marinedrugs-16-00210-f001){ref-type="fig"}). Compound **1** was found to be the first cembranoid possessing an unusual 6,9,2′-trioxaspiro\[bicycle(5,2,0)nonane-8,1′- cyclopentane\]-3′-one moiety in the molecule.

Stellatumolide B (**2**), \[α\]${}_{D}^{25}$ −59.4 (*c* 0.3, CHCl~3~), possessed the molecular formula C~20~H~28~O~4~ as indicated by HREIMS at *m/z* 332.1985, implying seven degrees of unsaturation. Similarly to compound **1**, the strong IR absorptions at ν~max~ 3420, 1752, and 1666 cm^--1^ indicated the presence of hydroxyl, ester carbonyl, and olefinic groups, respectively. The carbonyl group was identified as an α,β-unsaturated ester from the ^13^C NMR signals of three nonprotonated carbons at *δ*~C~ 170.3, 152.2, and 123.3. Moreover, two trisubstituted double bonds were deduced from NMR signals at *δ*~C~/*δ*~H~ 147.8 (C), 130.9 (C), 117.4 (CH)/5.16 (1H, s), and 129.1(CH)/ 4.97 (1H, dd) ([Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}). The ^13^C NMR spectrum, in addition to distortionless enhancement by polarization transfer (DEPT) and heteronuclear multiple quantum coherence (HMQC) experiments, showed 20 carbon signals, assigned to four methyls, six methylenes, one *sp^3^* oxymethine, two olefinic methines, and seven quaternary carbons (including four olefinic *sp^2^*, two oxygenated *sp^3^*, and one carbonyl carbons). As for compound **1**, three partial structures of consecutive spin systems were distinguished by analysis of COSY correlations ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}). Examination of the HMBC correlations of **2** enabled connection of these three partial structures, including the positioning of hydroxyl groups at C-7 and an ether linkage at C-4 and C-8 ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}). From the HMBC correlations detected from H~3~-18 (*δ*~H~ 1.48, s) to C-3 (*δ*~C~ 117.4, CH) and H-3 (*δ*~H~ 5.16, s) to C-2 (*δ*~C~ 147.8, C) and C-1 (*δ*~C~ 152.3, C), the C-2/C-3 location of the oxytrisubstituted double bond could be assigned. Furthermore, the HMBC correlations from H~3~-17 (*δ*~C~ 1.94, s) to C-1, C-15 (*δ*~C~ 123.3, C), and the carbonyl C-16 (*δ*~C~ 170.3, C), confirmed the C-1/C-2 location of the γ-lactone ring. In considering the degrees of unsaturation and molecular formula, an ether linkage was placed between C-4 and C-8.

Further detailed examination of 2D NMR correlations ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}) established the gross structure of **2** as 4,8-epoxy-7β-hydroxy-cembra-1(15),2,11-trien-16,2-olide. Careful investigation of NOESY correlations in combination with measuring distances between relevant protons in the MM2 energy-minimized model enabled resolution of the relative configuration of compound **2** ([Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}). The NOE interactions of H~3~-18 with H~3~-19 and H~3~-20, H~3~-20 with one of the methylene protons at C-10 (*δ*~H~ 1.82, dd, *J* = 14.5), H~2~-10 with H~3~-19, and H~3~-19 with H-7 (*δ*~H~ 3.44 dd, *J* = 7.0, 5.0) revealed that the methyl groups at C-4 and C-8 were on the same face as H-7, and assuming that H~3~-18 was α-oriented, both C-7 and C-8 were therefore of the *S*\* configuration. Moreover, the NOE correlations displayed by H~3~-17/H-14, H~3~-18/H-3, and H~3~-20/H-10 assigned the geometry of the double bonds at C-1/C-15, C-2/C-3, and C-11/C-12 as *Z*, *Z*, and *E*, respectively. On the basis of the above findings, the structure of stellatumolide B (**2**) was elucidated.

Stellatumolide C (**3**) was found to have the same molecular formula (C~20~H~28~O~4~) as compound **2** and the same hydroxyl and unsaturated γ-lactone functionalities on the basis of its HREIMS and IR spectra. The NMR data of **3** ([Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}) were found to be mostly identical to those of **2**, with the exception that the chemical signal of C-7 was found to be shifted upfield (Δ*δ*~C~ − 2.7 ppm) in comparison with that of **2**, and the variational *J* values of 9.5 and 5.0 Hz at H-7 of **3** relative to that of **2** (7.0 and 3.0 Hz). After interpretation of the 2D NMR spectra, in particular the NOE correlations including that of H~3~-18/H~3~-19, compound **3** was established as the 7-epimer of compound **2**.

Stellatumonin A (**4**) was isolated as a colorless oil (\[α\]${}_{D}^{25}$ −220, *c* 0.3, CHCl~3~) and possessed the molecular formula C~20~H~30~O~3~, as determined by HRESIMS (*m/z* 341.2091, \[M + Na\]^+^). The NMR spectroscopic features ([Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}) indicated that **4** was structurally similar to **9** ([Figure 6](#marinedrugs-16-00210-f006){ref-type="fig"}) \[[@B2-marinedrugs-16-00210],[@B7-marinedrugs-16-00210]\] from C-2 to C-12 in the fourteen-membered ring; however, an additional 1,14-double bond was observed. The planar structure of **4** was obtained by detailed investigation and interpretation of 2D NMR (COSY, HMQC, and HMBC) spectroscopic correlations ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}), and was determined to be 2,16:7,8-diepoxy-cembra-1(14),3,11-trien-15-ol. After elucidation of the structure of **4**, a natural marine compound **17** ([Figure 7](#marinedrugs-16-00210-f007){ref-type="fig"}) \[[@B31-marinedrugs-16-00210]\] was found to have the very similar structure. However, on comparison of the NMR data of both compounds, significant upfield shifts at C-2, C-3, C-12, C-14, C-16, and C-17 (Δ*δ*~C~ −3.5, −3.3, −2.2, −2.9, −1.5, and −4.0 ppm, respectively), and a downfield shift at C-13 (Δ*δ*~C~ + 3.8 ppm), in **4** relative to **17** were observed. Also, H-14 in **4** exhibited a significant downfield shift (Δ*δ*~H~ − 0.46 ppm) relative to that of **17**. The *E* geometry, instead of *Z* geometry as in **17**, for the C-14/C-1 double bond was thus suggested for **4**, and was consequently confirmed by the NOE interaction of H-14 with H~3~-17. Furthermore, detailed NOE correlation analysis of **4** ([Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}) confirmed the relative configuration at chiral carbons C-2, C-7, C-8, and C-15 to be 2*S*\*, *7S*\*, 8*S*\*, and 15*S*\*, respectively ([Figure 1](#marinedrugs-16-00210-f001){ref-type="fig"}).

The HRESIMS (*m/z* 348.2301, M^+^) and NMR data ([Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}) established the molecular formula of stellatumonin B (**5**) to be C~21~H~32~O~4~, with six degrees of unsaturation. The ^13^C NMR of **5** displayed 21 carbon signals ascribable to five methyls (including that of a methoxy group), seven methylenes, three methines, and six quaternary carbons. In addition, a trisubstituted epoxide (*δ*~C~/*δ*~H~ 62.0/2.84 and 60.7), a tetrasubstituted epoxide (*δ*~C~ 71.3 and 63.3, each C), two trisubstituted double bonds (*δ*~C~/*δ*~H~ 142.8, C; 134.6, C; 124.6, CH/5.24; and 120.6, CH/5.21), a quaternary dioxycarbon (*δ*~C~ 107.4, C), and an oxymethylene (*δ*~C~/*δ*~H~ H 68.8, CH~2~/3.64, and 3.88) were disclosed. The COSY and HMBC correlations, as depicted in [Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}, determined the positions of the two trisubstituted double bonds, the two epoxides, and the oxymethylene groups at C-3/C-4 and C-11/C-12, C-7/C-8 and C-1/C-15, and C-16, respectively, inferring the tetracyclic structure of **5** ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}). Furthermore, C-2 was determined to be the ketal carbon (*δ*~C~ 107.4), containing a methoxy group (*δ*~C~ 49.3, CH~3~), as supported by the HMBC correlation from protons of methoxy group to C-2. The gross structure of **5** was thus confirmed. The upfield chemical shifts (*δ*~C~ \< 20 ppm) of C-18 and C-20 and NOE correlations ([Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}) proved the *E* configuration of C-3/C-4 and C-11/C-12 double bonds of **5**. One of the H~2~-16 protons resonating at *δ*~H~ 3.88 was arbitrarily designated as H-16β, while the other as H-16α (*δ*~H~ 3.64). The NOE interactions of H-16β with 2-OCH~3~ protons, and H~3~-17 with H~2~-16, H-13, (*δ*~H~ 2.10) and H-14 (*δ*~H~ 1.82) reflected the β-orientations of the methoxy at C-2 and the oxygen of the epoxide at C-1/C-15. The significant NOE response of the olefinic H-3 with H-7 and other NOE correlations ([Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}) in **5** established the *trans* geometry of the 7.8-epoxide with an α-oriented H-7 and β-oriented H~3~-19. Thus, the relative configuration of compound **5** was determined.

The NMR spectroscopic data of **6** ([Table 1](#marinedrugs-16-00210-t001){ref-type="table"}) are similar to those of secosarcophinolide (**18**) \[[@B32-marinedrugs-16-00210]\], with the difference that the *n*-butoxy group at C-16 was replaced by a methoxy group in **6**. COSY and HMBC correlations further confirmed the molecular skeleton of **6** ([Figure 2](#marinedrugs-16-00210-f002){ref-type="fig"}). Analysis of the NOE corrections ([Figure 4](#marinedrugs-16-00210-f004){ref-type="fig"}) established *Z* geometry for 1,15- and 3,4-double bonds, and *E* geometry for the 11,12-double bond and *trans*-7,8-epoxide of **6**. Thus, the relative configuration of **6** was determined. This result could be further supported by NMR data of biscembranoids containing the same *cis*-β-methyl-α,β-conjugated enone \[[@B11-marinedrugs-16-00210],[@B33-marinedrugs-16-00210]\].

A plausible biosynthethic pathway of **1** from the possible precursor **19** was proposed as shown in [Scheme 1](#marinedrugs-16-00210-sch001){ref-type="scheme"}. The acid-catalyzed ring opening of the 3,4-epoxide of a postulated diepoxy intermediate **19** followed by the nucleophilic addition of the 2-hydroxy group at the cationic carbon C-4 led to the dioxaspiro intermediate **20**. Acid-catalyzed ring opening of 7,8-epoxide affords a carbonium ion intermediate **21** which after the nucleophilic attack of 3-hydroxy group at the cationic carbon C-8 from an upward orientation gives **1**.

In addition to the isolated new compounds (**1**--**6**), ten known cembrenoids (**7**--**16**) ([Figure 6](#marinedrugs-16-00210-f006){ref-type="fig"}) were also obtained from *S. stellatum*, including sarsolilide (**7**) \[[@B34-marinedrugs-16-00210],[@B35-marinedrugs-16-00210]\], a hydroperoxide (**8**) obtained by autoxidation of dihydrofuranocembrenoid \[[@B36-marinedrugs-16-00210]\] (+)-sarcophine (**9**) \[[@B2-marinedrugs-16-00210],[@B7-marinedrugs-16-00210]\], laevigatol B (**10**) \[[@B37-marinedrugs-16-00210]\], sarcophytonin E (**11**) \[[@B38-marinedrugs-16-00210]\], sarcophytonin C (**12**) \[[@B39-marinedrugs-16-00210]\], 17-hydroxysarcophytoxide (**13**) \[[@B40-marinedrugs-16-00210],[@B41-marinedrugs-16-00210]\], 7β-acetoxy-8α-hydroxydeepoxysarcophine (**14**) \[[@B42-marinedrugs-16-00210]\], 7β,8α-dihydroxydeepoxy-*ent*-sarcophine (**15**) \[[@B43-marinedrugs-16-00210]\], and crassumol A (**16***)* \[[@B38-marinedrugs-16-00210]\]. Among these cembranoids, compounds **8** and **14** were isolated from a natural source for the first time.

Cytotoxicities of metabolites **1**--**16** against the growth of human hepatocellular liver carcinoma (HepG2), human breast cancer (MDA-MB231), and human lung adenocarcinoma (A549) cell lines were screened. None of the metabolites exhibited inhibitory activity against the growth of the tested cancer cells (IC~50~ \> 20 μg/mL).

Furthermore, the in vitro anti-inflammatory activity of (+)-sarcophine (**9**) on inhibition of the expression of COX-2 and iNOS proteins in the lipopolysaccharide (LPS)-stimulated mouse leukaemic monocyte macrophage cell line (RAW 264.7) was further evaluated, due to the sufficient quantity of **9** (104.3 mg) isolated from this investigation. The results showed that **9** could effectively inhibit the LPS-induced expression of iNOS protein at 50 and 100 μM. Compound **9** also could significantly inhibit the expression of COX-2 at 25--100 μM ([Figure 8](#marinedrugs-16-00210-f008){ref-type="fig"}).

Comparing with compound **9**, some other nonselective COX-2 inhibitors, such as ibuprofen (half maximal inhibitory concentration IC~50~ for COX-2: 30 μM) \[[@B44-marinedrugs-16-00210]\] and aspirin (IC~50~ for COX-2: 1.36 mM; for iNOS: 3 mM) \[[@B45-marinedrugs-16-00210],[@B46-marinedrugs-16-00210]\], appear to be less effective in inhibiting COX-2 than **9**, whereas the selective COX-2 inhibitor celecoxib (IC50 for COX-2: 0.072 μM) \[[@B44-marinedrugs-16-00210]\] is more effective than **9**. Also, the inhibiting activity for iNOS expression of **9** was found to be 25--100 μM, showing that **9** has higher iNOS-inhibitory activity than aspirin (IC~50~: 3 mM).

3. Experimental Section {#sec3-marinedrugs-16-00210}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00210}
------------------------------------

Optical rotations were measured on a JASCO P-1020 polarimeter (JASCO Corporation, Tokyo, Japan). Ultraviolet (UV) spectra were recorded on a JASCO V-650 spectrophotometer (JASCO Corporation). Infrared (IR) spectra were recorded on JASCO FT/IR-4100 Fourier transform infrared spectrophotometer (JASCO Corporation, Tokyo, Japan). NMR spectra were recorded on a Varian Unity INOVA500 FT-NMR (Varian Inc., Palo Alto, CA, USA) instrument at 500 MHz for ^1^H and 125 MHz for ^13^C in CDCl~3~, and the chemical shifts were referenced to residual signals of TMS (*δ*~H~ 0.00 ppm) and the CDCl~3~ (*δ*~C~ 77.0 ppm). EIMS and ESIMS data were obtained by BRUKER APEX II mass spectrometer (Bruker, Bremen, Germany). Silica gel (230--400 mesh, Merck, Darmstadt, Germany) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical thin-layer chromatography (TLC). High-performance liquid chromatography was performed on a Hitachi L-2455 high-performance liquid chromatography (HPLC) apparatus (Hitachi Ltd., Tokyo, Japan) with a Supelco C18 column (250 mm × 21.2 mm, 5 μm).

3.2. Animal Material {#sec3dot2-marinedrugs-16-00210}
--------------------

The soft coral *Sarcophyton stellatum* Kukenthal (Alcyoniidea) was collected by hand via self-contained underwater breathing apparatus (SCUBA) at a depth of 10--15 m along the coast of Dongsha Atoll, Taiwan, and stored in at −20 °C until extraction. A voucher sample (NHSC 2009-04) was deposited at Department of Marine Biotechnology and Resources, National Sun Yat-sen University. The soft coral was identified by one of the authors (C.-F.D.).

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-16-00210}
-----------------------------

The frozen bodies of *S. stellatum* (2.5 kg, wet wt.) were minced and extracted thoroughly with EtOAc. The combined extract was concentrated by reduced pressure and the solvent-free extract (39.2 g) was fractionated on a column of silica gel using pure *n*-hexane, EtOAc-*n*-hexane (1:100 to 10:1, gradient), and subsequently pure EtOAc as eluting solvents to yield 20 fractions (F1 to F20). Fractions F7 and F8 eluted with EtOAc-*n*-hexane (1:6 and 1:4, respectively) were combined and further purified over a silica gel column using EtOAc-*n*-hexane (1:8) and RP-18 gel column using MeOH--H~2~O (1:1) as eluents. The purified fraction was then chromatographed on RP-18 HPLC using MeOH--H~2~O (6:1 to 5:1, gradient) to afford **1** (1.0 mg), **6** (0.9 mg), and **7** (1.3 mg), eluted by MeOH--H~2~O (6:1); and **2** (3.2 mg) and **3** (3.7 mg), eluted by MeOH--H~2~O (5:1), subsequently. F10 and F11 eluted with EtOAc-*n*-hexane (1:1 and 2:1, respectively) were combined together and separated over a Si gel column using EtOAc--*n*-hexane (1:4), RP-18 gel column using MeOH--H~2~O (5:1), and on RP-18 HPLC using MeOH--H~2~O (5:1 to 4:1, gradient) to yield **5** (3.2 mg), **8** (0.8 mg), **9** (104.3 mg), **10** (4.7 mg), and **11** (5.8 mg), successively. F12 and F13 eluted with EtOAc-*n*-hexane (4:1 and 6:1, respectively) were combined and chromatographed on Si gel 60 column using EtOAc-*n*-hexane (1:2), RP-18 gel column using MeOH--H~2~O (2:1), and on RP-18 HPLC using MeOH--H~2~O (3:1 to 2:1, gradient) to yield **12** (2.6 mg), **13** (4.6 mg), and **14** (2.2 mg). Finally, F14 eluted with EtOAc-*n*-hexane (8:1) was isolated on Si gel 60 column using EtOAc-*n*-hexane (1:1), RP-18 gel column using MeOH--H~2~O (1:1), and on RP-18 HPLC using MeOH--H~2~O (2:1 to 4:1, gradient) to give **4** (3.1 mg), **15** (2.1 mg), and **16** (7.8 mg).

Stellatumolide A (**1**): colorless oil; \[α\]${}_{D}^{25}$ +57.2 (*c* 0.1, CHCl~3~); IR (neat) ν~max~ 3445, 2925, 2857, 1760, 1680, 1455, 1379, 1259, 1227, 1092, 1037 and 762 cm^--1^; UV (MeOH) λ~max~ 204 (log ε = 3.5); ^13^C (125 MHz, CDCl~3~) and ^1^H NMR (500 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}, respectively; ^13^C (125 MHz, C~6~D~6~) δ 170.0 (C, C-16), 157.8 (C, C-1), 130.8 (C, C-12), 129.9 (CH, C-11), 129.5 (C, C-15), 114.0 (C, C-2), 92.1 (C, C-4), 83.8 (C, C-8), 72.2 (CH, C-3), 71.2 (CH, C-7), 41.2 (CH~2~, C-9), 40.1 (CH~2~, C-13), 39.1 (CH~2~, C-5), 32.1 (CH~2~, C-6), 24.7 (CH~2~, C-10), 22.6 (CH~2~, C-14), 23.2 (CH~3~, C-19), 20.8 (CH~3~, C-18), 16.5 (CH~3~, C-20), 8.7 (CH~3~, C-17); ^1^H (500 MHz, C~6~D~6~) δ 5.15 (1H, d, *J* = 11.0 Hz, H-11), 4.19 (1H, s, H-3), 3.93 (1H, d, *J* = 10.0 Hz, H-7), 2.29 (2H, m, H~2~-10), 2.12 (1H, dd, *J* = 13.0, 13.0 Hz, H-14), 2.01 (1H, ddd, *J* = 13.0, 8.0, 8.0 Hz, H-14),1.89 (1H, m, H-13), 1.80 (1H, m, H-9), 1.78 (1H, m, H-13), 1.73 (3H, s, H~3~-18), 1.68 (1H, m, H-9), 1.56 (3H, s, H~3~-20), 1.50 (1H, m, H-6), 1.49 (3H, s, H~3~-17), 1.30 (2H, m, H~2~-5), 1.22 (1H, m, H-6), 1.08 (3H, s, H~3~-19); ESIMS *m/z* 371 \[M + Na\]^+^, 353 \[M − H~2~O + Na\]^+^; HRESIMS *m/z* 371.1832 \[M + Na\]^+^ (calcd. for C~20~H~28~O~5~Na, 371.1834).

Stellatumolide B (**2**): colorless oil; \[α\]${}_{D}^{25}$ −59.4 (*c* 0.3, CHCl~3~); IR (neat) ν~max~ 3420, 2928, 2859, 1752, 1666, 1457, 1376, 1063, and 1020 cm^--1^; UV (MeOH) λ~max~ 275 (log ε = 4.3); ^13^C (125 MHz, CDCl~3~) and ^1^H NMR (500 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}, respectively; HREIMS *m/z* 332.1985 (calcd. for C~20~H~28~O~4~, 332.1988).

Stellatumolide C (**3**): colorless oil; \[α\]${}_{D}^{25}$ −52.5 (*c* 0.3, CHCl~3~); IR (neat) ν~max~ 3419, 2965, 2927, 2856, 1749, 1666, 1457, 1377, 1063, and 1019 cm^--1^; UV (MeOH) λ~max~ 275 (log ε = 4.3); ^13^C (125 MHz, CDCl~3~) and ^1^H NMR (500 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}, respectively; HREIMS *m/z* 332.1989 (calcd. for C~20~H~28~O~4~, 332.1988\].

Stellatumonin A (**4**): colorless oil; \[α\]${}_{D}^{25}$ −220 (*c* 0.3, CHCl~3~); IR (neat) ν~max~ 3421, 2927, 2863, 1729, 1453, 1380, 1247, 1136, 1043 and 767 cm^--1^; ^13^C (125 MHz, CDCl~3~) and ^1^H NMR (500 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}, respectively; HRESIMS *m/z* 341.2091, \[M + Na\]^+^ (calcd. For C~20~H~30~O~3~Na, 341.2093).

Stellatumonin B (**5**): colorless oil; \[α\]${}_{D}^{25}$ −105 (*c* 0.2, CHCl~3~); IR (neat) ν~max~ 2959, 2927, 2857, 1734, 1455, 1385, and 1049 cm^--1^; ^13^C (125 MHz, CDCl~3~) and ^1^H NMR (500 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}, respectively. HRESIMS *m/z* 348.2301 (calcd. For C~21~H~32~O~4~, 348.2301).

Stellatumonone (**6**): colorless oil; \[α\]${}_{D}^{25}$ −63.5 (*c* 0.1, CHCl~3~); IR (neat) ν~max~ 2925, 2859, 1720, 1673, 1619, 1447, 1298, 1253 and 1093 cm^--1^; UV (MeOH) λ~max~ 203 (log ε = 4.4); ^13^C (125 MHz, CDCl~3~) and ^1^H NMR (500 MHz, CDCl~3~) data, see [Table 1](#marinedrugs-16-00210-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00210-t002){ref-type="table"}, respectively; HREIMS *m/z* 346.2143 (calcd. for C~21~H~30~O~4~, 346.2144\].

3.4. Cytotoxicity Assay {#sec3dot4-marinedrugs-16-00210}
-----------------------

The cancer cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays of the isolated metabolites were performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric method \[[@B47-marinedrugs-16-00210],[@B48-marinedrugs-16-00210]\]. Compound is considered inactive when IC~50~ \> 20 μg/mL. The positive control used is doxorubicin.

3.5. In Vitro Anti-Inflammatory Assay {#sec3dot5-marinedrugs-16-00210}
-------------------------------------

RAW264.7 cells were purchased from the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cell were cultured in DMEM, supplemented with RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin G, and 100 μg/mL streptomycin (Gibco/BRL, Gran Island, NY, USA), at 37 °C in an incubator with 5% CO~2~. RAW 264.7 cells were seeded onto a 6-well plate with 2 × 10^6^ cell per well and cultured for 24 h. The cells were pretreated with the compound **9** for 1 h and treated with lipopolysaccharide (LPS, 1 μg/mL) from *Escherichia coli* 055:B5 (Sigma-Aldrich, St Louis, MO, USA) in the presence or absence of the compound **9** (25, 50, and 100 µM). After 24 h LPS treatment, the cell lysates were prepared using Cell Lysis Buffer (Cell Signalling Technology, Beverly, MA, USA). The expression of COX-2 and iNOS proteins was measured using Western blotting analysis.

3.6. Western Blotting Analysis {#sec3dot6-marinedrugs-16-00210}
------------------------------

Protein concentrations were measured using a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA). Protein extracts were boiled, loaded into sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and electrotransferred to polyvinylidene fluoride (PVDF) membranes. After blocking in 5% nonfat milk in TBST buffer (20 mM Tris-HCl, 120 mM NaCl, and 0.1% Tween 20) for 1 h, the membranes were incubated with antibodies for COX-2 (\#4842), iNOS (\#13120), and β-actin (\#3700) (all purchased from Cell Signaling Technology, Danvers, MA, USA) at 4 °C with gentle agitation overnight. The membranes were then washed and incubated with horseradish peroxidase-labelled rabbit and mouse secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) for 2 h at room temperature. After successive washes, the membranes were developed with an enhanced chemoluminescence (ECL) kit (Amersham Biosciences, Buckinghamshire, UK), and blots were visualized using a LAS3000 system (Fujifilm, Tokyo, Japan). Densitometric analysis was performed with ImageJ software (National Institute of Health, Bethesda, MD, USA).

3.7. Statistical Analysis {#sec3dot7-marinedrugs-16-00210}
-------------------------

The data are expressed as the mean ± SD. One-way ANOVA followed by Tukey's post-hoc test (Graphpad Prism 5.0, GraphPad Software, San Diego, CA, USA) was used to compare multiple groups according to the experiments. *p* values \< 0.05 were considered statistically significant.

4. Conclusions {#sec4-marinedrugs-16-00210}
==============

Six new polyoxygenated cembrane-based diterpenoids, **1**--**6**, together with ten known related compounds (**7**--**16**), were isolated from the Formosan soft coral *Sarcophyton stellatum*. Compound **1** possessed an unusual spiroketal unit between the oxetane (C-2/C-4) and the γ-lactone ring (C-2/C-16) in the cembranoid, suggesting the potential to discover more new molecular structures from marine organisms and warrant the further discovery of new medicines from the ocean. Compound **9** could effectively inhibit the accumulation of the proinflammatory COX-2 and iNOS proteins in LPS-stimulated RAW264.7 macrophage cells in a dose-response manner. Thus, compound **9** might be useful for discovery of an effective anti-inflammatory agent.

Financial supported was mainly provided by the Ministry of Science and Technology of Taiwan to J.-H.S. The authors extend their appreciation to the International Scientific Partnership Program ISPP at King Saud University for funding this research work through ISPP-116.

^1^H, ^13^C, DEPT, HMQC, COSY, HMBC and NOESY spectra of new compounds **1**--**6** are available online at <http://www.mdpi.com/1660-3397/16/6/210/s1>. Figure S1: ^1^H NMR spectrum of **1** in CDCl~3~, Figure S2: ^13^C NMR spectrum of **1** in CDCl~3~, Figure S3: DEPT spectra of **1** in CDCl~3~, Figure S4: HMQC spectrum of **1** in CDCl~3~, Figure S5: COSY spectrum of **1** in CDCl~3~, Figure S6: HMBC spectrum of **1** in CDCl~3~, Figure S7: NOESY spectrum of **1** in CDCl~3~, Figure S8: ^1^H NMR spectrum of **1** in C~6~D~6~, Figure S9: ^13^C NMR spectrum of **1** in C~6~D~6~. Figure S10: DEPT spectrum of **1** in C~6~D~6~, Figure S11: COSY spectrum of **1** in C~6~D~6~, Figure S12: HMBC spectrum of **1** in C~6~D~6~. Figure S13: NOESY spectrum of **1** in C~6~D~6~, Figure S14: ^1^H NMR spectrum of **2** in CDCl~3~, Figure S15: ^13^C NMR spectrum of **2** in CDCl~3~, Figure S16: DEPT spectra of **2** in CDCl~3~, Figure S17: HMQC spectrum of **2** in CDCl~3~, Figure S18: COSY spectrum of **2** in CDCl~3~, Figure S19: HMBC spectrum of **2** in CDCl~3~. Figure S20: NOESY spectrum of **2** in CDCl~3~, Figure S21: ^1^H NMR spectrum of **3** in CDCl~3~, Figure S22: ^13^C NMR spectrum of **3** in CDCl~3~, Figure S23: DEPT spectra of **3** in CDCl~3~, Figure S24: HMQC spectrum of **3** in CDCl~3~, Figure S25: COSY spectrum of **3** in CDCl~3~, Figure S26: HMBC spectrum of **3** in CDCl~3~, Figure S27: NOESY spectrum of **3** in CDCl~3~, Figure S28: ^1^H NMR spectrum of **4** in CDCl~3~, Figure S29: ^13^C NMR spectrum of **4** in CDCl~3~, Figure S30: DEPT spectra of **4** in CDCl~3~**,** Figure S31: HMQC spectrum of **4** in CDCl~3~, Figure S32: COSY spectrum of **4** in CDCl~3~, Figure S33: HMBC spectrum of **4** in CDCl~3~, Figure S34: NOESY spectrum of **4** in CDCl~3~, Figure S35: ^1^H NMR spectrum of **5** in CDCl~3~, Figure S36: ^13^C NMR spectrum of **5** in CDCl~3~, Figure S37: DEPT spectra of **5** in CDCl~3~, Figure S38: HMQC spectrum of **5** in CDCl~3~, Figure S39: COSY spectrum of **5** in CDCl~3~, Figure S40: HMBC spectrum of **5** in CDCl~3~**,** Figure S41: NOESY spectrum of **5** in CDCl~3~, Figure S42: ^1^H NMR spectrum of **6** in CDCl~3~, Figure S43: ^13^C NMR spectrum of **6** in CDCl~3~, Figure S44: HMQC spectrum of **6** in CDCl~3~, Figure S45: COSY spectrum of **6** in CDCl~3~, Figure S46: HMBC spectrum of **6** in CDCl~3~, Figure S47: NOESY spectrum of **6** in CDCl~3~.
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![Structures of compounds **1**--**6**.](marinedrugs-16-00210-g001){#marinedrugs-16-00210-f001}

![Selected COSY and HMBC correlations of **1**--**6**.](marinedrugs-16-00210-g002){#marinedrugs-16-00210-f002}

![HMBC (**upper**) in CDCl~3~ and NOESY (**lower**) spectra of **1** in C~6~D~6~.](marinedrugs-16-00210-g003){#marinedrugs-16-00210-f003}

###### 

Selected nuclear Overhauser effect (NOE) correlations for **1**, **2**, and **4**--**6.**

![](marinedrugs-16-00210-g004a)

![](marinedrugs-16-00210-g004b)

![CONFLEX/MMFF94s-optimized most abundant conformers of compound **1** and their relative abundance: (**1a**) 85.86 kcal/mol (54.702%); (**1b**) 86.17 kcal/mol (32.668%); (**1c**) 86.74 kcal/mol (12.576%).](marinedrugs-16-00210-g005){#marinedrugs-16-00210-f005}

![Structures of known compounds **7**--**16**.](marinedrugs-16-00210-g006){#marinedrugs-16-00210-f006}

![Known natural products, sarcophyton B (**17**) and secosarcophinolide (**18**), used for spectral data comparison.](marinedrugs-16-00210-g007){#marinedrugs-16-00210-f007}

![Proposed biosynthetic pathway for **1.**](marinedrugs-16-00210-sch001){#marinedrugs-16-00210-sch001}

![The effect of compound **9** on the protein expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in mouse leukaemic monocyte macrophage (RAW 264.7) cells. Cells were pretreated with compound **9** at a concentration of 25, 50, and 100 μM for 1 h, and then treated with 1 μg/mL lipopolysaccharide (LPS) for 24 h. Band image and the densitometric quantifications of Western blotting results is shown (**upper**). β-actin was used as the internal control protein. The band intensity was quantitated using ImageJ software. The bar graph (**lower**) shows the mean ± SD values from three independent experimental results. \*\* *p* \< 0.01; \*\*\* *p* \< 0.001 compared with LPS-alone group.](marinedrugs-16-00210-g008){#marinedrugs-16-00210-f008}

marinedrugs-16-00210-t001_Table 1

###### 

^13^C NMR data of compounds **1**--**6** and **18**.

  Position   1 ^a^           2 ^a^          3 ^a^          4 ^a^          5 ^a^          6 ^a^          18 ^c,d^
  ---------- --------------- -------------- -------------- -------------- -------------- -------------- --------------
  1          157.9 (C) ^b^   152.2 (C)      152.2 (C)      147.8 (C)      63.3 (C)       155.3 (C)      151.0 (C)
  2          113.4 (C)       147.8 (C)      148.2 (C)      76.2 (CH)      107.4 (C)      197.8 (C)      196.7 (C)
  3          71.1 (CH)       117.4 (CH)     116.5 (CH)     125.3 (CH)     120.6 (CH)     125.3 (CH)     123.8 (CH)
  4          92.2 (C)        73.7 (C)       74.2 (C)       136.1 (C)      142.8 (C)      153.2 (C)      155.8 (C)
  5          38.3 (CH~2~)    40.4 (CH~2~)   38.8 (CH~2~)   36.2 (CH~2~)   37.6 (CH~2~)   29.2 (CH~2~)   37.6 (CH~2~)
  6          31.5 (CH~2~)    26.7 (CH~2~)   26.9 (CH~2~)   25.9 (CH~2~)   25.7 (CH~2~)   25.9 (CH~2~)   24.9 (CH~2~)
  7          71.3(CH)        77.3 (CH)      74.6 (CH)      61.9 (CH)      62.0 (CH)      62.3 (CH)      62.0 (CH)
  8          83.5 (C)        74.6 (C)       74.9 (C)       59.7 (C)       60.7 (C)       60.6 (C)       60.5 (C)
  9          40.4 (CH~2~)    37.8 (CH~2~)   38.0 (CH~2~)   39.2 (CH~2~)   37.1 (CH~2~)   37.6 (CH~2~)   37.2 (CH~2~)
  10         24.0 (CH~2~)    21.6 (CH~2~)   22.1 (CH~2~)   24.1 (CH~2~)   22.5 (CH~2~)   22.9 (CH~2~)   22.7 (CH~2~)
  11         129.2 (CH)      129.1 (CH)     128.5 (CH)     123.6 (CH)     124.6 (CH)     125.1 (CH)     125.9 (CH)
  12         130.6 (C)       130.9 (C)      131.4 (C)      132.7 (C)      134.6 (C)      134.4 (C)      134.3 (C)
  13         39.6 (CH~2~)    38.7 (CH~2~)   38.3 (CH~2~)   38.2 (CH~2~)   33.7 (CH~2~)   36.3 (CH~2~)   36.6 (CH~2~)
  14         22.2 (CH~2~)    21.8 (CH~2~)   22.2 (CH~2~)   120.1 (CH)     21.6 (CH~2~)   28.8 (CH~2~)   29.3 (CH~2~)
  15         128.8 (C)       123.3 (C)      123.7 (C)      77.4 (C)       71.3 (C)       125.0 (C)      127.8 (C)
  16         171.1 (C)       170.3 (C)      170.3 (C)      78.8 (CH~2~)   68.8 (CH~2~)   168.5 (C)      168.8 (C)
  17         8.6 (CH~3~)     8.7 (CH~3~)    8.8 (CH~3~)    22.1 (CH~3~)   11.7 (CH~3~)   14.1 (CH~3~)   15.1 (CH~3~)
  18         20.1 (CH~3~)    29.7 (CH~3~)   29.5 (CH~3~)   17.1 (CH~3~)   16.8 (CH~3~)   24.2 (CH~3~)   19.6 (CH~3~)
  19         22.5 (CH~3~)    26.1 (CH~3~)   25.6 (CH~3~)   16.3 (CH~3~)   17.8 (CH~3~)   17.1 (CH~3~)   17.4 (CH~3~)
  20         16.3 (CH~3~)    15.6 (CH~3~)   15.9 (CH~3~)   16.6 (CH~3~)   16.3 (CH~3~)   16.1 (CH~3~)   15.5 (CH~3~)
  OMe                                                                     49.3 (CH~3~)   52.0 (CH~3~)   

^a^ Spectra recorded in CDCl~3~ at 125 MHz at 25 °C. ^b^ Attached protons were determined by distortionless enhancement by polarization transfer (DEPT) experiments. The values are in ppm downfield from tetramethylsilane (TMS). ^c^ Spectra recorded in CDCl~3~ at 100 MHz at 25 °C. ^d^ The ^13^C data of the *n*-butoxy moiety were omitted.
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###### 

^1^H NMR (CDCl~3~, 500 MHz) spectral data for compounds **1**--**6**.

  Position   1 ^a^                                       2 ^a^                3 ^a^                                4 ^a^                               5 ^a^                           6 ^a^
  ---------- ------------------------------------------- -------------------- ------------------------------------ ----------------------------------- ------------------------------- ----------------------------------------
  2                                                                                                                5.27 d (9.5)                                                        
  3          4.27 s                                      5.16 s               5.21 s                               5.37 d (9.5)                        5.21 s                          6.10 s
  5          1.72 m; 1.88 m                              1.90 m; 1.97 m       1.79, m; 2.09, m                     2.32 dd (14.0, 8.0); 2.09 m         2.28 2H, m                      2.70 m; 2.97 m
  6          1.94 2H, m                                  1.48 2H, m           1.49 m; 1.54 m                       1.52 m; 1.83 m                      1.70 m; 1.88 m                  1.61 m; 2.00 m
  7          4.27 br d (10.0) ^b^                        3.44 dd (7.0, 5.0)   3.52 dd (9.5, 3.0)                   2.85 dd (5.0, 5.0)                  2.84 dd (7.5, 4.0)              2.65 dd (8.0, 3.0)
  9          1.82 m; 1.92 m                              1.52, m ; 1.63 m     1.49 m; 1.64 m                       1.05 dd (14.0, 14.0, 5.0); 2.07 m   1.47, dd (13.0, 13.0); 1.98 m   1.30 m; 2.02 m
  10         2.00, m (11.0); 2.44, m                     1.82, m; 2.26 m      1.87, m; 2.17 ddd (14.0, 7.0, 7.0)   2.09 m; 2.11 m                      1.94 m; 2.12 m                  2.00 m; 2.18 m
  11         5.26 d (11.0)                               4.97 dd (6.5, 6.5)   5.00 dd (7.0, 7.0)                   4.88 dd (7.0, 7.0)                  5.24, m                         5.05 dd (6.5, 6.5)
  13         2.07 dd (13.0, 13.0); 2.40 m                2.22 m; 2.30 m       2.25 m; 2.30 m                       2.58 2H, m                          2.13 2H, m                      2.16 2H, m
  14         2.33 dd (13.0, 13.0); 2.53 dd (13.0, 7.5)   2.56 2H, m           2.57 2H, dd (7.5, 7.5)               5.68 ddd (8.5, 6.5, 2.0)            1.82 m; 2.14 m                  2.40 dd (14.0, 7.0); 2.45 dd (14, 7.0)
  16                                                                                                               3.57 d (9.0); 3.94 d (9.0)          3.64 d (10.0); 3.88 d (10.0)    
  17         1.87 s                                      1.94 s               1.95 s                               1.41 s                              1.40 s                          1.92 s
  18         1.69 s                                      1.48 s               1.54 s                               1.82 s                              1.86 s                          1.92 s
  19         1.19 s                                      1.18 s               1.23 s                               1.25 s                              1.28 s                          1.23 s
  20         1.87 s                                      1.63 s               1.63 s                               1.63 s                              1.59 s                          1.58 s
  OMe                                                                                                                                                  3.20 s                          3.68 s

^a^ Spectra recorded at 25 °C. ^b^ Coupling constants (*J* values) in Hz in parentheses.

[^1]: These authors contributed equally to this work.
